世界のX連鎖低リン酸血症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global X-Linked Hypophosphatemia Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z6094 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、X連鎖低リン酸血症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（投薬、矯正手術、その他）、用途別市場規模（病院、診療所、診断センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・X連鎖低リン酸血症の市場動向 ・企業の競争状況、市場シェア ・X連鎖低リン酸血症の種類別市場規模（投薬、矯正手術、その他） ・X連鎖低リン酸血症の用途別市場規模（病院、診療所、診断センター、その他） ・X連鎖低リン酸血症の北米市場規模2016-2027（アメリカ、カナダ） ・X連鎖低リン酸血症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・X連鎖低リン酸血症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・X連鎖低リン酸血症の中南米市場規模2016-2027（メキシコ、ブラジル） ・X連鎖低リン酸血症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Ultragenyx Pharmaceutical、Kyowa Hakko Kirin、Nestle、Merck、Pfizer、Roche、Koninklijke DSM、ADM Alliance Nutrition、Eli Lily、Validus Pharmaceuticals） ・結論

X-Linked Hypophosphatemia (XLH) is a genetic disorder characterized by low levels of phosphate in the blood. Phosphate levels in the blood are low as phosphate is abnormally processed in kidneys, which causes a loss of phosphate in urine and leads to soft and weak bones.
Geographically, the Americas is anticipated to dominate the global X-linked hypophosphatemia market owing to a well-developed healthcare sector, rising prevalence of X-linked hypophosphatemia, and growing demand for vitamin supplements. Additionally, the increasing number of patients with genetic disorders, short stature, and growing healthcare expenditure have boosted the growth of the market in the region. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.

Market Analysis and Insights: Global X-Linked Hypophosphatemia Market
The global X-Linked Hypophosphatemia market size is projected to reach US$ 32 million by 2026, from US$ 28 million in 2019, at a CAGR of 2.0% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global X-Linked Hypophosphatemia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global X-Linked Hypophosphatemia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global X-Linked Hypophosphatemia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global X-Linked Hypophosphatemia market.

Global X-Linked Hypophosphatemia Scope and Market Size
X-Linked Hypophosphatemia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global X-Linked Hypophosphatemia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medication
Corrective Surgery
Others

Segment by Application
Hospitals
Clinics
Diagnostic Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Ultragenyx Pharmaceutical
Kyowa Hakko Kirin
Nestle
Merck
Pfizer
Roche
Koninklijke DSM
ADM Alliance Nutrition
Eli Lily

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global X-Linked Hypophosphatemia Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medication
1.2.3 Corrective Surgery
1.2.4 Others
1.3 Market by Application
1.3.1 Global X-Linked Hypophosphatemia Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global X-Linked Hypophosphatemia Market Perspective (2016-2027)
2.2 X-Linked Hypophosphatemia Growth Trends by Regions
2.2.1 X-Linked Hypophosphatemia Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 X-Linked Hypophosphatemia Historic Market Share by Regions (2016-2021)
2.2.3 X-Linked Hypophosphatemia Forecasted Market Size by Regions (2022-2027)
2.3 X-Linked Hypophosphatemia Industry Dynamic
2.3.1 X-Linked Hypophosphatemia Market Trends
2.3.2 X-Linked Hypophosphatemia Market Drivers
2.3.3 X-Linked Hypophosphatemia Market Challenges
2.3.4 X-Linked Hypophosphatemia Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top X-Linked Hypophosphatemia Players by Revenue
3.1.1 Global Top X-Linked Hypophosphatemia Players by Revenue (2016-2021)
3.1.2 Global X-Linked Hypophosphatemia Revenue Market Share by Players (2016-2021)
3.2 Global X-Linked Hypophosphatemia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by X-Linked Hypophosphatemia Revenue
3.4 Global X-Linked Hypophosphatemia Market Concentration Ratio
3.4.1 Global X-Linked Hypophosphatemia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by X-Linked Hypophosphatemia Revenue in 2020
3.5 X-Linked Hypophosphatemia Key Players Head office and Area Served
3.6 Key Players X-Linked Hypophosphatemia Product Solution and Service
3.7 Date of Enter into X-Linked Hypophosphatemia Market
3.8 Mergers & Acquisitions, Expansion Plans

4 X-Linked Hypophosphatemia Breakdown Data by Type
4.1 Global X-Linked Hypophosphatemia Historic Market Size by Type (2016-2021)
4.2 Global X-Linked Hypophosphatemia Forecasted Market Size by Type (2022-2027)

5 X-Linked Hypophosphatemia Breakdown Data by Application
5.1 Global X-Linked Hypophosphatemia Historic Market Size by Application (2016-2021)
5.2 Global X-Linked Hypophosphatemia Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America X-Linked Hypophosphatemia Market Size (2016-2027)
6.2 North America X-Linked Hypophosphatemia Market Size by Type
6.2.1 North America X-Linked Hypophosphatemia Market Size by Type (2016-2021)
6.2.2 North America X-Linked Hypophosphatemia Market Size by Type (2022-2027)
6.2.3 North America X-Linked Hypophosphatemia Market Size by Type (2016-2027)
6.3 North America X-Linked Hypophosphatemia Market Size by Application
6.3.1 North America X-Linked Hypophosphatemia Market Size by Application (2016-2021)
6.3.2 North America X-Linked Hypophosphatemia Market Size by Application (2022-2027)
6.3.3 North America X-Linked Hypophosphatemia Market Size by Application (2016-2027)
6.4 North America X-Linked Hypophosphatemia Market Size by Country
6.4.1 North America X-Linked Hypophosphatemia Market Size by Country (2016-2021)
6.4.2 North America X-Linked Hypophosphatemia Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe X-Linked Hypophosphatemia Market Size (2016-2027)
7.2 Europe X-Linked Hypophosphatemia Market Size by Type
7.2.1 Europe X-Linked Hypophosphatemia Market Size by Type (2016-2021)
7.2.2 Europe X-Linked Hypophosphatemia Market Size by Type (2022-2027)
7.2.3 Europe X-Linked Hypophosphatemia Market Size by Type (2016-2027)
7.3 Europe X-Linked Hypophosphatemia Market Size by Application
7.3.1 Europe X-Linked Hypophosphatemia Market Size by Application (2016-2021)
7.3.2 Europe X-Linked Hypophosphatemia Market Size by Application (2022-2027)
7.3.3 Europe X-Linked Hypophosphatemia Market Size by Application (2016-2027)
7.4 Europe X-Linked Hypophosphatemia Market Size by Country
7.4.1 Europe X-Linked Hypophosphatemia Market Size by Country (2016-2021)
7.4.2 Europe X-Linked Hypophosphatemia Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific X-Linked Hypophosphatemia Market Size (2016-2027)
8.2 Asia-Pacific X-Linked Hypophosphatemia Market Size by Type
8.2.1 Asia-Pacific X-Linked Hypophosphatemia Market Size by Type (2016-2021)
8.2.2 Asia-Pacific X-Linked Hypophosphatemia Market Size by Type (2022-2027)
8.2.3 Asia-Pacific X-Linked Hypophosphatemia Market Size by Type (2016-2027)
8.3 Asia-Pacific X-Linked Hypophosphatemia Market Size by Application
8.3.1 Asia-Pacific X-Linked Hypophosphatemia Market Size by Application (2016-2021)
8.3.2 Asia-Pacific X-Linked Hypophosphatemia Market Size by Application (2022-2027)
8.3.3 Asia-Pacific X-Linked Hypophosphatemia Market Size by Application (2016-2027)
8.4 Asia-Pacific X-Linked Hypophosphatemia Market Size by Region
8.4.1 Asia-Pacific X-Linked Hypophosphatemia Market Size by Region (2016-2021)
8.4.2 Asia-Pacific X-Linked Hypophosphatemia Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America X-Linked Hypophosphatemia Market Size (2016-2027)
9.2 Latin America X-Linked Hypophosphatemia Market Size by Type
9.2.1 Latin America X-Linked Hypophosphatemia Market Size by Type (2016-2021)
9.2.2 Latin America X-Linked Hypophosphatemia Market Size by Type (2022-2027)
9.2.3 Latin America X-Linked Hypophosphatemia Market Size by Type (2016-2027)
9.3 Latin America X-Linked Hypophosphatemia Market Size by Application
9.3.1 Latin America X-Linked Hypophosphatemia Market Size by Application (2016-2021)
9.3.2 Latin America X-Linked Hypophosphatemia Market Size by Application (2022-2027)
9.3.3 Latin America X-Linked Hypophosphatemia Market Size by Application (2016-2027)
9.4 Latin America X-Linked Hypophosphatemia Market Size by Country
9.4.1 Latin America X-Linked Hypophosphatemia Market Size by Country (2016-2021)
9.4.2 Latin America X-Linked Hypophosphatemia Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa X-Linked Hypophosphatemia Market Size (2016-2027)
10.2 Middle East & Africa X-Linked Hypophosphatemia Market Size by Type
10.2.1 Middle East & Africa X-Linked Hypophosphatemia Market Size by Type (2016-2021)
10.2.2 Middle East & Africa X-Linked Hypophosphatemia Market Size by Type (2022-2027)
10.2.3 Middle East & Africa X-Linked Hypophosphatemia Market Size by Type (2016-2027)
10.3 Middle East & Africa X-Linked Hypophosphatemia Market Size by Application
10.3.1 Middle East & Africa X-Linked Hypophosphatemia Market Size by Application (2016-2021)
10.3.2 Middle East & Africa X-Linked Hypophosphatemia Market Size by Application (2022-2027)
10.3.3 Middle East & Africa X-Linked Hypophosphatemia Market Size by Application (2016-2027)
10.4 Middle East & Africa X-Linked Hypophosphatemia Market Size by Country
10.4.1 Middle East & Africa X-Linked Hypophosphatemia Market Size by Country (2016-2021)
10.4.2 Middle East & Africa X-Linked Hypophosphatemia Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Ultragenyx Pharmaceutical
11.1.1 Ultragenyx Pharmaceutical Company Details
11.1.2 Ultragenyx Pharmaceutical Business Overview
11.1.3 Ultragenyx Pharmaceutical X-Linked Hypophosphatemia Introduction
11.1.4 Ultragenyx Pharmaceutical Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.1.5 Ultragenyx Pharmaceutical Recent Development
11.2 Kyowa Hakko Kirin
11.2.1 Kyowa Hakko Kirin Company Details
11.2.2 Kyowa Hakko Kirin Business Overview
11.2.3 Kyowa Hakko Kirin X-Linked Hypophosphatemia Introduction
11.2.4 Kyowa Hakko Kirin Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.2.5 Kyowa Hakko Kirin Recent Development
11.3 Nestle
11.3.1 Nestle Company Details
11.3.2 Nestle Business Overview
11.3.3 Nestle X-Linked Hypophosphatemia Introduction
11.3.4 Nestle Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.3.5 Nestle Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck X-Linked Hypophosphatemia Introduction
11.4.4 Merck Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer X-Linked Hypophosphatemia Introduction
11.5.4 Pfizer Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche X-Linked Hypophosphatemia Introduction
11.6.4 Roche Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Koninklijke DSM
11.7.1 Koninklijke DSM Company Details
11.7.2 Koninklijke DSM Business Overview
11.7.3 Koninklijke DSM X-Linked Hypophosphatemia Introduction
11.7.4 Koninklijke DSM Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.7.5 Koninklijke DSM Recent Development
11.8 ADM Alliance Nutrition
11.8.1 ADM Alliance Nutrition Company Details
11.8.2 ADM Alliance Nutrition Business Overview
11.8.3 ADM Alliance Nutrition X-Linked Hypophosphatemia Introduction
11.8.4 ADM Alliance Nutrition Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.8.5 ADM Alliance Nutrition Recent Development
11.9 Eli Lily
11.9.1 Eli Lily Company Details
11.9.2 Eli Lily Business Overview
11.9.3 Eli Lily X-Linked Hypophosphatemia Introduction
11.9.4 Eli Lily Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.9.5 Eli Lily Recent Development
11.10 Validus Pharmaceuticals
11.10.1 Validus Pharmaceuticals Company Details
11.10.2 Validus Pharmaceuticals Business Overview
11.10.3 Validus Pharmaceuticals X-Linked Hypophosphatemia Introduction
11.10.4 Validus Pharmaceuticals Revenue in X-Linked Hypophosphatemia Business (2016-2021)
11.10.5 Validus Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global X-Linked Hypophosphatemia Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medication
Table 3. Key Players of Corrective Surgery
Table 4. Key Players of Others
Table 5. Global X-Linked Hypophosphatemia Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global X-Linked Hypophosphatemia Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global X-Linked Hypophosphatemia Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global X-Linked Hypophosphatemia Market Share by Regions (2016-2021)
Table 9. Global X-Linked Hypophosphatemia Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global X-Linked Hypophosphatemia Market Share by Regions (2022-2027)
Table 11. X-Linked Hypophosphatemia Market Trends
Table 12. X-Linked Hypophosphatemia Market Drivers
Table 13. X-Linked Hypophosphatemia Market Challenges
Table 14. X-Linked Hypophosphatemia Market Restraints
Table 15. Global X-Linked Hypophosphatemia Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global X-Linked Hypophosphatemia Market Share by Players (2016-2021)
Table 17. Global Top X-Linked Hypophosphatemia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in X-Linked Hypophosphatemia as of 2020)
Table 18. Ranking of Global Top X-Linked Hypophosphatemia Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by X-Linked Hypophosphatemia Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players X-Linked Hypophosphatemia Product Solution and Service
Table 22. Date of Enter into X-Linked Hypophosphatemia Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 25. Global X-Linked Hypophosphatemia Revenue Market Share by Type (2016-2021)
Table 26. Global X-Linked Hypophosphatemia Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global X-Linked Hypophosphatemia Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global X-Linked Hypophosphatemia Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global X-Linked Hypophosphatemia Revenue Market Share by Application (2016-2021)
Table 30. Global X-Linked Hypophosphatemia Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global X-Linked Hypophosphatemia Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 33. North America X-Linked Hypophosphatemia Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America X-Linked Hypophosphatemia Market Size by Application (2016-2021) (US$ Million)
Table 35. North America X-Linked Hypophosphatemia Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America X-Linked Hypophosphatemia Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America X-Linked Hypophosphatemia Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe X-Linked Hypophosphatemia Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe X-Linked Hypophosphatemia Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe X-Linked Hypophosphatemia Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe X-Linked Hypophosphatemia Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe X-Linked Hypophosphatemia Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific X-Linked Hypophosphatemia Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific X-Linked Hypophosphatemia Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific X-Linked Hypophosphatemia Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific X-Linked Hypophosphatemia Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific X-Linked Hypophosphatemia Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America X-Linked Hypophosphatemia Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America X-Linked Hypophosphatemia Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America X-Linked Hypophosphatemia Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America X-Linked Hypophosphatemia Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America X-Linked Hypophosphatemia Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa X-Linked Hypophosphatemia Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa X-Linked Hypophosphatemia Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa X-Linked Hypophosphatemia Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa X-Linked Hypophosphatemia Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa X-Linked Hypophosphatemia Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa X-Linked Hypophosphatemia Market Size by Country (2022-2027) & (US$ Million)
Table 62. Ultragenyx Pharmaceutical Company Details
Table 63. Ultragenyx Pharmaceutical Business Overview
Table 64. Ultragenyx Pharmaceutical X-Linked Hypophosphatemia Product
Table 65. Ultragenyx Pharmaceutical Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 66. Ultragenyx Pharmaceutical Recent Development
Table 67. Kyowa Hakko Kirin Company Details
Table 68. Kyowa Hakko Kirin Business Overview
Table 69. Kyowa Hakko Kirin X-Linked Hypophosphatemia Product
Table 70. Kyowa Hakko Kirin Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 71. Kyowa Hakko Kirin Recent Development
Table 72. Nestle Company Details
Table 73. Nestle Business Overview
Table 74. Nestle X-Linked Hypophosphatemia Product
Table 75. Nestle Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 76. Nestle Recent Development
Table 77. Merck Company Details
Table 78. Merck Business Overview
Table 79. Merck X-Linked Hypophosphatemia Product
Table 80. Merck Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 81. Merck Recent Development
Table 82. Pfizer Company Details
Table 83. Pfizer Business Overview
Table 84. Pfizer X-Linked Hypophosphatemia Product
Table 85. Pfizer Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 86. Pfizer Recent Development
Table 87. Roche Company Details
Table 88. Roche Business Overview
Table 89. Roche X-Linked Hypophosphatemia Product
Table 90. Roche Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 91. Roche Recent Development
Table 92. Koninklijke DSM Company Details
Table 93. Koninklijke DSM Business Overview
Table 94. Koninklijke DSM X-Linked Hypophosphatemia Product
Table 95. Koninklijke DSM Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 96. Koninklijke DSM Recent Development
Table 97. ADM Alliance Nutrition Company Details
Table 98. ADM Alliance Nutrition Business Overview
Table 99. ADM Alliance Nutrition Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 100. ADM Alliance Nutrition Recent Development
Table 101. Eli Lily Company Details
Table 102. Eli Lily Business Overview
Table 103. Eli Lily X-Linked Hypophosphatemia Product
Table 104. Eli Lily Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 105. Eli Lily Recent Development
Table 106. Validus Pharmaceuticals Company Details
Table 107. Validus Pharmaceuticals Business Overview
Table 108. Validus Pharmaceuticals X-Linked Hypophosphatemia Product
Table 109. Validus Pharmaceuticals Revenue in X-Linked Hypophosphatemia Business (2016-2021) & (US$ Million)
Table 110. Validus Pharmaceuticals Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global X-Linked Hypophosphatemia Market Share by Type: 2020 VS 2027
Figure 2. Medication Features
Figure 3. Corrective Surgery Features
Figure 4. Others Features
Figure 5. Global X-Linked Hypophosphatemia Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Others Case Studies
Figure 10. X-Linked Hypophosphatemia Report Years Considered
Figure 11. Global X-Linked Hypophosphatemia Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global X-Linked Hypophosphatemia Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global X-Linked Hypophosphatemia Market Share by Regions: 2020 VS 2027
Figure 14. Global X-Linked Hypophosphatemia Market Share by Regions (2022-2027)
Figure 15. Global X-Linked Hypophosphatemia Market Share by Players in 2020
Figure 16. Global Top X-Linked Hypophosphatemia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in X-Linked Hypophosphatemia as of 2020
Figure 17. The Top 10 and 5 Players Market Share by X-Linked Hypophosphatemia Revenue in 2020
Figure 18. Global X-Linked Hypophosphatemia Revenue Market Share by Type (2016-2021)
Figure 19. Global X-Linked Hypophosphatemia Revenue Market Share by Type (2022-2027)
Figure 20. North America X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America X-Linked Hypophosphatemia Market Share by Type (2016-2027)
Figure 22. North America X-Linked Hypophosphatemia Market Share by Application (2016-2027)
Figure 23. North America X-Linked Hypophosphatemia Market Share by Country (2016-2027)
Figure 24. United States X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe X-Linked Hypophosphatemia Market Share by Type (2016-2027)
Figure 28. Europe X-Linked Hypophosphatemia Market Share by Application (2016-2027)
Figure 29. Europe X-Linked Hypophosphatemia Market Share by Country (2016-2027)
Figure 30. Germany X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific X-Linked Hypophosphatemia Market Share by Type (2016-2027)
Figure 38. Asia-Pacific X-Linked Hypophosphatemia Market Share by Application (2016-2027)
Figure 39. Asia-Pacific X-Linked Hypophosphatemia Market Share by Region (2016-2027)
Figure 40. China X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America X-Linked Hypophosphatemia Market Share by Type (2016-2027)
Figure 48. Latin America X-Linked Hypophosphatemia Market Share by Application (2016-2027)
Figure 49. Latin America X-Linked Hypophosphatemia Market Share by Country (2016-2027)
Figure 50. Mexico X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa X-Linked Hypophosphatemia Market Share by Type (2016-2027)
Figure 54. Middle East & Africa X-Linked Hypophosphatemia Market Share by Application (2016-2027)
Figure 55. Middle East & Africa X-Linked Hypophosphatemia Market Share by Country (2016-2027)
Figure 56. Turkey X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE X-Linked Hypophosphatemia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Ultragenyx Pharmaceutical Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 60. Kyowa Hakko Kirin Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 61. Nestle Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 65. Koninklijke DSM Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 66. ADM Alliance Nutrition Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 67. Eli Lily Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 68. Validus Pharmaceuticals Revenue Growth Rate in X-Linked Hypophosphatemia Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---